On Tuesday (February 6) lead minister from the Canadian federal government listened to the doubts and concerns of a Senate in need of answers ahead of passing the highly anticipated cannabis legalization bill.

After clearing the house of commons Bill C-45, the cannabis act headed to the Canadian Senate for the last hearing process before being approved. A point of debate for this bill has become the exact timeline for it be enacted and when consumers will be able to purchase recreational cannabis.


Last year, the Canadian Prime Minister dismissed the July 1, 2018, deadline, which was previously reported to have been the government’s target date for enacting the cannabis act.

“The date will not be July 1, I can assure you of that,” Trudeau told the TVA network in Quebec. “I don’t know where that date came from.” The Canadian leader said instead the government was looking at “next summer” to be the target date for legalization.

Potential delay due to time it takes to enforce bill

Now the logistics behind the Senate process have caused a timing issue for the Canadian government. Health Minister Ginette Petitpas Taylor revealed the government will wait up to three months to wait for licensed producers (LPs) to comply with the mandates of the bill.

“The federal government will wait eight to 12 weeks after the legislation is passed before officially lifting the 95-year-old prohibition on cannabis,” The Globe and Mail wrote.

Minister Petitpas Taylor said the government is “still very confident that we’ll be able to meet our goal of July, 2018,” for the enactment of the cannabis act, according to iPolitics.

However, their report indicated the health minister said government officials will need time to comply with the bill after it obtains Royal Assent.

“That comment comes after a government official raised the prospect that bills require a coming into force date after receiving Royal Assent. That could delay implementation for eight to 12 weeks, meaning the deadline could be overshot by months, and that the Senate would need to pass the bill by end of May for Canadians to buy cannabis legally in July,” iPolitics wrote.

Deepak Anand, vice president of government relations at Cannabis Compliance told the Investing News Network (INN) that this unclear timeline for the cannabis act is a result of progress of the Senate hearings.

“I don’t think it’s a matter of not getting approved to the Senate, I just think the Senate is going to take its time in approving the bill, which could delay legalization if that were what to happen, beyond July,” Anand said. “That’s the only risk at this point.”

Bruce Linton, CEO of Canopy Growth (TSX:WEED) said he’s not as concerned with the exact date of enactment for the bill. “[E]very minute that we have longer just allows us to have more assets available and to negotiate better deals,” Linton told The Globe and Mail.

Investor Takeaway

Outside of a significant delay, cannabis investors have waited patiently to see what companies in the sector will be able to deliver with the recreational market available to them.

Analysts in the industry have waited for legalization to evaluate the companies in the space completely, with a full look at their business accounting for recreational products.

“It’s not until the rubber hits the road in the second half of the year with the roll-out of legal adult-use marijuana in Canada that we envision  potential negative operational catalysts (rapid capacity expansion, execution of provincial retail distribution frameworks) that could slow down current trends,” Canaccord Genuity analysts Matt Bottomley and Neil Maruoka wrote in their January research note.

As part of their industry update report for the cannabis market in February, Canaccord wrote they do not expect any imminent negative catalysts for the industry except for the potential of a “meaningful delay” to the legalization of recreational cannabis thanks to the Senate.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less

Part of “Rooted in Good” CSR Platform, “Feed the Block” Gives Back Through Strategic Social Partnerships with Local Organizations Focused on Food Insecurity

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced a multi-state fundraising initiative in which proceeds will benefit 24 locally run food banks, homeless shelters and nonprofits working to proactively address the needs of those facing food insecurity in communities across America. This effort is a part of the Strategic Social Partnerships pillar within Curaleaf’s “Rooted in Good” Corporate Social Responsibility platform.

Keep reading... Show less

On September 8, 2020, Aurora Cannabis Inc. (NYSE:ACB) stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora’s stock fell approximately 11.6% in just one day. Since May 2020, Aurora’s stock is down approximately $10.00 per share

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. The suit alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a “business transformation plan” that would purportedly “better align the business financially with the current realities of the cannabis market.”

Keep reading... Show less

  • Exclusive patent licensed from University of Idaho.
  • Mustard-derived fumigation of stored food – targeting vegetables and potatoes.
  • Leading agrochemical for sprout suppression – chlorpropham – banned by European Union on Oct. 8, 2020.
  • Appointment of Scientific Advisor Dr. Matthew J. Morra, professor emeritus of soil biochemistry at University of Idaho.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the exclusive patent licensing from the University of Idaho pertaining to a natural biopesticide mustard-based treatment of stored produce and other foods, particularly sprout suppression of potatoes.

Keep reading... Show less